Intellia Therapeutics NTLA Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $134.7M-13.4% | $155.46M-19.6% | $193.39M+23.8% | $156.17M+23.1% | $126.88M-32.9% | ||
| $241.29M-18.0% | $294.42M-7.3% | $317.66M+4.7% | $303.48M-19.5% | $376.87M-8.6% | ||
| $9.13M-3.6% | $9.47M-14.3% | $11.05M-2.7% | $11.35M+8.1% | $10.5M+23.3% | ||
| $466.45M-11.6% | $527.71M-9.3% | $581.94M+17.3% | $495.95M-10.1% | $551.39M-13.8% | ||
| $15.52M-12.2% | $17.67M-13.5% | $20.42M-10.5% | $22.81M-9.2% | $25.12M-8.2% | ||
| $758.78M-9.9% | $842.13M-9.0% | $925.28M+2.9% | $898.89M-8.8% | $986.16M-17.2% | ||
| $18.8M-7.2% | $20.25M+52.7% | $13.26M+35.3% | $9.8M-20.7% | $12.36M-15.3% | ||
| $630K-91.4% | $7.29M-40.5% | $12.25M-28.6% | $17.15M-17.0% | $20.66M0.0% | ||
| $76.45M-26.4% | $103.88M+10.8% | $93.73M-1.9% | $95.5M-15.2% | $112.59M+1.6% | ||
| $137.84M-19.3% | $170.73M-3.5% | $176.85M-3.7% | $183.64M-11.0% | $206.24M-35.4% | ||
| $12K0.0% | $12K0.0% | $12K+20.0% | $10K0.0% | $10K0.0% | ||
| -$2.69B-3.7% | -$2.59B-3.8% | -$2.49B-4.2% | -$2.39B-4.4% | -$2.29B-5.3% | ||
| $620.94M-7.5% | $671.39M-10.3% | $748.42M+4.6% | $715.26M-8.3% | $779.92M-10.6% | ||
| $758.78M-9.9% | $842.13M-9.0% | $925.28M+2.9% | $898.89M-8.8% | $986.16M-17.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Intellia Therapeutics cover its short-term obligations?
- Its current ratio is 6.10 — current assets exceed current liabilities.
- Where does Intellia Therapeutics's balance sheet data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.